Viking Global Investors LP Travere Therapeutics, Inc. Transaction History
Viking Global Investors LP
- $29.9 Billion
- Q1 2025
A detailed history of Viking Global Investors LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Viking Global Investors LP holds 2,601,922 shares of TVTX stock, worth $44 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
2,601,922
Previous 2,901,925
10.34%
Holding current value
$44 Million
Previous $50.6 Million
7.76%
% of portfolio
0.16%
Previous 0.17%
Shares
2 transactions
Others Institutions Holding TVTX
# of Institutions
239Shares Held
101MCall Options Held
1.79MPut Options Held
555K-
Armistice Capital, LLC New York, NY8.87MShares$150 Million2.42% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$129 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$127 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$84.8 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$81.1 Million0.11% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.09B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...